Lonza & Octane Biotech v. Miltenyi Biotec: 6-Patent Cell Therapy Dispute Ends in Dismissal With Prejudice
Lonza Walkersville and Octane Biotech jointly sued Miltenyi Biotec in Maryland federal court, asserting six patents covering automated cell therapy manufacturing systems against Miltenyi’s CliniMACS Prodigy platform. The case ran for 1,181 days before ending in a joint motion to dismiss with prejudice — suggesting the parties reached a negotiated resolution that permanently forecloses re-litigation.
A Six-Patent Showdown Over Automated Cell Therapy Manufacturing
Filed on 28 January 2022 in the District of Maryland, this case pitted Lonza Walkersville, Inc. and Octane Biotech, Inc. against Miltenyi Biotec, Inc. in a patent infringement action spanning six US patents. The asserted patents — US9534195B2, US10723986B2, US11447745B2, US10844338B1, US11371018B2, and US9701932B2 — collectively cover automated cell therapy manufacturing processes and systems. The accused product was Miltenyi’s CliniMACS Prodigy System, encompassing the Prodigy Instrument, its associated Tubing Sets, and the CliniMACS Electroporator.
The case closed on 23 April 2025 via a Joint Motion to Dismiss, with the court ordering plaintiffs’ claims dismissed with prejudice. Dismissal with prejudice is a final adjudication on the merits under federal procedural rules: the plaintiffs cannot re-file the same claims against Miltenyi on these six patents. That both parties moved jointly — rather than one party seeking dismissal over the other’s objection — strongly suggests a negotiated resolution, likely a settlement or cross-licensing arrangement, though no financial terms have been disclosed in the public record.
At 1,181 days, this litigation spanned more than three years, which is consistent with complex multi-patent biotech cases in district courts that involve substantial claim construction and technical expert work. The joint nature of the dismissal motion suggests the parties may have resolved the dispute through a commercial agreement during or after discovery. What remains unknown is whether Miltenyi obtained a licence to the asserted patents, whether Lonza and Octane received any compensation, and whether any non-assertion covenants accompany the resolution.
Filing to Dismissed with Prejudice in 1181 days
1,181 days — over 3 years in litigation, above the median for multi-patent biotech district court cases
Dismissed with prejudice: what the joint motion means for both parties
Dismissed with prejudice bars any future re-filing on these patents
A dismissal with prejudice is a final, court-ordered termination of the claims. Under Federal Rule of Civil Procedure 41, the plaintiffs cannot re-file the same infringement claims against Miltenyi on the six asserted patents. A joint motion signals mutual consent — neither party was forced out; both agreed to end the litigation on these terms. Courts treat this as a final judgment on the merits for res judicata purposes.
Permanent bar on re-litigationLonza and Octane permanently waive the right to re-sue on these patents
By joining the dismissal motion, Lonza Walkersville and Octane Biotech have permanently surrendered their ability to re-assert these six patents against Miltenyi for the accused CliniMACS Prodigy products. In practice, this outcome typically reflects a negotiated commercial resolution — whether a licence, a cross-licence, or a settlement payment — though the public record does not confirm financial terms.
Claims permanently extinguishedMiltenyi receives permanent protection from these specific patent claims
Miltenyi Biotec exits the litigation with a court order permanently barring these six patent claims from being re-asserted by the same plaintiffs. If a licence was granted as part of a settlement, Miltenyi can continue CliniMACS Prodigy sales with legal certainty. Even absent a licence, the dismissal with prejudice provides a strong res judicata defence against any future suit by Lonza or Octane on these same patents.
Res judicata protection grantedCell therapy IP landscape: licensing is the dominant resolution pathway
This case reinforces the pattern in automated cell therapy manufacturing disputes: prolonged multi-patent litigation frequently concludes through commercial negotiation rather than a court verdict. For sector competitors, the six asserted patents remain in force and enforceable against third parties. The dismissal provides no invalidity finding — these patents survive as granted and could be asserted against other players in the automated cell therapy manufacturing market.
Patents survive — third parties remain at riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Lonza Walkersville, Inc. | Company | Biotech and cell therapy technology companies — co-holders of 6 automated cell manufacturing patentsSearch in Eureka ↗ |
| Co-Plaintiff | Octane Biotech, Inc. | Company | Search in Eureka ↗ |
| Defendant | Miltenyi Biotec, Inc. | Company | Miltenyi Biotec, Inc. — developer and marketer of the CliniMACS Prodigy cell therapy manufacturing platformSearch in Eureka ↗ |
| Plaintiff counsel | Anne Elise Li | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elissa N. Tenenbaum | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Helen O. Osun | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Stronski | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Karla I Arias | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert Kornweiss | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Shannon Lentz | Attorney | Counsel for Lonza Walkersville, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Crowell & Moring, LLP | Law Firm | Representing Lonza Walkersville, Inc.Search in Eureka ↗ |
| Defendant counsel | Ahmed Jamal Davis | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | Brandon J. Pakkebier | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth M. Flanagan | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | Madelyn S. McCormick | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan A. Chacon | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | W. Chad Shear | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant counsel | Yun Dong | Attorney | Counsel for Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant law firm | Cirrus Aircraft | Law Firm | Representing Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant law firm | Cooley LLP | Law Firm | Representing Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC | Law Firm | Representing Miltenyi Biotec, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Maryland District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order tracks the parties’ joint motion verbatim, directing that ‘plaintiffs’ claims are dismissed with prejudice.’ The phrase ‘with prejudice’ carries significant legal weight: it constitutes a final adjudication that extinguishes the plaintiffs’ infringement claims on the six asserted patents permanently as against Miltenyi Biotec. Critically, no invalidity finding was made — the patents emerge intact and enforceable. The joint nature of the motion distinguishes this from a court-compelled dismissal and is consistent with a negotiated commercial resolution whose precise terms remain outside the public record.
US9534195B2 and 5 further patents — automated cell therapy manufacturing systems
The six asserted patents span a range of application dates from 2013 (US9534195B2, app. no. US13/906719 and US9701932B2, app. no. US13/906698) through to 2020 (US10844338B1, app. no. US16/928655 and US11371018B2, app. no. US16/668745), suggesting a layered prosecution strategy designed to capture evolving automated cell therapy manufacturing technology. The portfolio collectively addresses closed-system automated platforms for GMP-grade cell culture, processing, and electroporation — the core workflow required for cell and gene therapy product manufacturing.
This portfolio is strategically significant because automated, closed-system cell therapy manufacturing is a critical bottleneck in the commercial-scale production of CAR-T and other advanced cell therapies. Miltenyi’s CliniMACS Prodigy is one of the leading platforms in this space, making it a high-value litigation target. The fact that Lonza and Octane assembled six patents spanning nearly a decade of prosecution reflects a deliberate effort to build blocking coverage across instrument design, consumables (tubing sets), and genetic modification hardware (electroporation). Competitors operating in the GMP cell manufacturing platform market should treat this portfolio as a material freedom-to-operate risk.
Should your platform run an FTO against US9534195B2 and the Lonza/Octane cell therapy portfolio?
Any company developing, commercialising, or supplying automated closed-system cell therapy manufacturing platforms — including GMP bioreactors, integrated tubing consumables, or electroporation hardware — should assess exposure to this six-patent portfolio. The portfolio covers multiple layers of the CliniMACS Prodigy workflow, meaning point-design-arounds at the instrument level may be insufficient if tubing or electroporation elements also fall within claim scope. The dismissal with prejudice provides no safe harbour for third parties.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to run structured freedom-to-operate analysis against the full Lonza/Octane cell therapy portfolio. Eureka maps independent and dependent claim scope across all six patents, identifies published prior art relevant to invalidity arguments, and surfaces related continuation or divisional applications that may extend coverage. Use Eureka to benchmark your platform design against the claims before committing to a commercial launch strategy in the automated cell therapy manufacturing sector.
Run a freedom-to-operate analysis on US9534195B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent disputes in automated cell therapy manufacturing
Explore related patent infringement cases involving automated cell therapy and bioprocessing platform technology in US federal district courts.
What this case signals for the cell therapy manufacturing IP landscape
Six live patents, a 3-year litigation, and a joint dismissal — here is what competitive teams need to take away.
All six asserted patents remain fully enforceable against third parties
The dismissal with prejudice carries no invalidity finding. US9534195B2, US10723986B2, US11447745B2, US10844338B1, US11371018B2, and US9701932B2 were never adjudicated on the merits. Competing automated cell therapy platform developers who have not secured licences remain exposed to infringement assertions from Lonza or Octane.
Joint dismissal in multi-patent biotech cases typically precedes commercial resolution
In high-stakes biotech platform disputes, joint motions to dismiss with prejudice — particularly after 3+ years of litigation — are strongly consistent with licence or settlement outcomes. IP teams monitoring this space should treat the resolution as a signal that the patent portfolio was commercially viable enough to negotiate around, not to invalidate.
Lonza v Miltenyi — key questions answered
Lonza Walkersville and Octane Biotech asserted six US patents: US9534195B2, US10723986B2, US11447745B2, US10844338B1, US11371018B2, and US9701932B2. All cover automated cell therapy manufacturing systems and processes. The accused product was Miltenyi’s CliniMACS Prodigy System, including the Prodigy Instrument, Tubing Sets, and CliniMACS Electroporator.
The case was dismissed with prejudice pursuant to a joint motion filed by both parties on 23 April 2025. Dismissal with prejudice is a permanent termination: Lonza and Octane cannot re-file the same infringement claims against Miltenyi on the six asserted patents. The joint nature of the motion is consistent with a negotiated settlement or licensing resolution, though financial terms are not in the public record.
Yes. The dismissal with prejudice contains no invalidity finding. All six patents — US9534195B2, US10723986B2, US11447745B2, US10844338B1, US11371018B2, and US9701932B2 — remain in force and enforceable. The dismissal only bars Lonza and Octane from re-asserting these specific claims against Miltenyi; third-party competitors in the automated cell therapy manufacturing space remain potentially exposed.
The case ran for 1,181 days, from 28 January 2022 to 23 April 2025 — over three years. This duration is consistent with complex multi-patent biotech litigation in US district courts, which typically involves extensive claim construction proceedings, technical expert discovery, and substantial motion practice before reaching a resolution.
The CliniMACS Prodigy System is Miltenyi Biotec’s automated, closed-system platform for GMP-grade cell therapy manufacturing. It includes the Prodigy Instrument, associated Tubing Sets, and the CliniMACS Electroporator. Lonza and Octane alleged this system infringed their portfolio of six patents covering automated cell culture, closed-system bioprocessing, and electroporation-based cell modification — core steps in CAR-T and other advanced cell therapy production workflows.
PatSnap Eureka searches patents and litigation data to answer instantly.